| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.79▼ | 3.81▼ | 3.81▼ | 3.73▼ | 3.43▲ |
| MA10 | 3.80▼ | 3.67▲ | 3.61▲ | 3.66▼ | 3.22▲ |
| MA20 | 3.62▲ | 3.48▲ | 3.43▲ | 3.41▲ | 2.79▲ |
| MA50 | 3.32▲ | 3.19▲ | 3.16▲ | 3.13▲ | 2.66▲ |
| MA100 | 3.01▲ | 2.82▲ | 2.82▲ | 2.75▲ | 3.28▲ |
| MA200 | 2.80▲ | 2.70▲ | 2.62▲ | 2.56▲ | 5.86▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.008▼ | 0.028▲ | 0.037▲ | 0.009▲ | 0.111▲ |
| RSI | 56.332▲ | 58.475▲ | 59.621▲ | 54.032▲ | 62.806▲ |
| STOCH | 46.518 | 78.496 | 79.186 | 68.079 | 77.196 |
| WILL %R | -43.609 | -39.189 | -37.299 | -56.122 | -28.967 |
| CCI | 2.216 | 51.871 | 69.820 | 17.069 | 136.271▲ |
|
Tuesday, April 15, 2025 09:00 AM
Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
|
|
Tuesday, April 15, 2025 06:00 AM
INVENTIVA Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage ...
|
|
Tuesday, April 01, 2025 04:00 PM
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 3.791 | 3.81 | 3.50 | 3.50 | 10,522 |
| 30/04/25 | 3.69 | 3.726 | 3.50 | 3.70 | 36,732 |
| 28/04/25 | 3.83 | 3.87 | 3.72 | 3.8046 | 9,203 |
| 25/04/25 | 3.77 | 3.90 | 3.77 | 3.89 | 5,289 |
| 24/04/25 | 3.69 | 3.84 | 3.69 | 3.77 | 10,566 |
| 23/04/25 | 3.90 | 4.05 | 3.7701 | 3.91 | 38,965 |
| 22/04/25 | 3.79 | 3.9891 | 3.57 | 3.83 | 60,776 |
| 21/04/25 | 3.47 | 3.61 | 3.26 | 3.56 | 30,014 |
| 17/04/25 | 3.43 | 3.44 | 3.16 | 3.36 | 15,372 |
| 16/04/25 | 3.39 | 3.4177 | 3.27 | 3.31 | 8,253 |
|
|
||||
|
|
||||
|
|